153 related articles for article (PubMed ID: 34825855)
21. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
22. The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.
Chen M; Wang Z; Liu Z; Liu N; Fang W; Zhang H; Jin X; Li J; Zhao W; Qu H; Song F; Chang Z; Li Y; Tang Y; Xu C; Zhang X; Wang X; Peng Z; Cai J; Li J; Shen L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291942
[TBL] [Abstract][Full Text] [Related]
23. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
24. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites?
Maiorano MFP; Messina C; Maiello E; Cormio G; Maiorano BA
BJOG; 2024 Jul; 131(8):1157-1159. PubMed ID: 38164107
[TBL] [Abstract][Full Text] [Related]
27. [New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].
Galienne M; Rodrigues M
Bull Cancer; 2021; 108(7-8):675-676. PubMed ID: 33994164
[No Abstract] [Full Text] [Related]
28. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
29. Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM; Makker V
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
31. Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer.
Oh MS; Chae YK
J Immunother; 2019; 42(2):51-54. PubMed ID: 30247204
[TBL] [Abstract][Full Text] [Related]
32. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis.
Jin C; Zhu X; Huang X; Gong T; Wei Z; You J
J Comp Eff Res; 2022 Feb; 11(3):203-212. PubMed ID: 35023361
[No Abstract] [Full Text] [Related]
34. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
36. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
[TBL] [Abstract][Full Text] [Related]
38. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
39. Impact of programmed cell death protein 1 inhibitor therapy on the survival of patients with advanced or recurrent uterine cancers: a meta-analysis.
Liang KW; Chen LJ; Wang CH; Ma KS; Hsia LH; Wang PH
Front Immunol; 2024; 15():1331994. PubMed ID: 38562939
[TBL] [Abstract][Full Text] [Related]
40. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]